The blood-based biomarkers market size has grown rapidly in recent years. It will grow from $23.13 billion in 2024 to $26.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth observed in the past can be attributed to the increasing global incidence of cancer, a higher adoption of personalized medicine, more funding in biomarker research, a rise in clinical trials involving biomarkers, and an increase in the approval of companion diagnostics.
The blood-based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth during the forecast period is expected to be driven by the expansion of AI and machine learning in biomarker analysis, a higher demand for early disease detection, the growth of telemedicine and remote diagnostics, the increasing prevalence of chronic diseases, and greater health awareness among consumers. Key trends during this period will include AI-driven biomarker discovery, advancements in liquid biopsy, integration of multi-omics, development of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the blood-based biomarkers market. Cardiovascular diseases, which encompass disorders affecting the heart and blood vessels such as coronary artery disease, heart failure, and stroke, are becoming more common due to risk factors such as poor diet and rising obesity rates. Blood-based biomarkers play a crucial role in diagnosing and monitoring these diseases by offering valuable information on disease progression, risk assessment, and treatment response through measurable substances in the blood. A global health research initiative by the National Center for Biotechnology Information in September 2024 projected a 90% increase in cardiovascular disease cases from 2025 to 2050, with cardiovascular deaths expected to reach 35.6 million by 2050. This rising incidence of cardiovascular diseases is contributing to the market growth for blood-based biomarkers.
Leading companies in the blood-based biomarkers market are focusing on technological innovations, such as high-accuracy blood biomarker tests, to assist in diagnosing diseases such as Alzheimer’s disease. These tests use specific biomarkers in the blood to detect or monitor health conditions with high precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, introduced the LucentAD p-Tau 217 test, a high-accuracy blood biomarker test designed to help physicians diagnose Alzheimer’s disease in adults with cognitive impairment. The test measures phosphorylated tau protein at threonine 217 (p-Tau 217), which is strongly linked to Alzheimer’s pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test provides over 90% accuracy, fulfilling stringent diagnostic criteria, and is meant to be used alongside other diagnostic tools rather than independently.
In December 2023, Danaher, a US-based provider of diagnostic, life sciences, and environmental solutions, acquired Abcam for $5.7 billion. This acquisition allows Danaher to enhance its life sciences portfolio by incorporating Abcam’s leading protein consumables and research tools. Abcam, a UK-based life sciences company, specializes in the development and distribution of research tools, including antibodies, assays, and reagents.
Major players in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG.
North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blood-based biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the blood-based biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Blood-based biomarkers are substances in the blood that can be measured to indicate the presence, progression, or response to a disease. They are primarily used for early detection, helping to personalize treatment plans and monitor treatment effectiveness with minimal invasiveness.
These biomarkers can be categorized into several types, including genetic, protein, metabolic, cell-based, and epigenetic biomarkers. Genetic biomarkers, which are based on DNA or RNA, identify genetic variations, mutations, or expression patterns linked to specific diseases or treatment responses. They are utilized in various advanced technologies, such as next-generation sequencing, polymerase chain reaction, immunoassays, and mass spectrometry. These biomarkers play a critical role in diagnosing and monitoring diseases such as cancer, cardiovascular conditions, neurological disorders, and immunological diseases. Key users of these biomarkers include hospitals, clinics, diagnostic labs, research institutes, and other healthcare providers.
The blood-based biomarkers market research report is one of a series of new reports that provides blood-based biomarkers market statistics, including the blood-based biomarkers industry global market size, regional shares, competitors with the blood-based biomarkers market share, detailed blood-based biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the blood-based biomarkers industry. This blood-based biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The blood-based biomarkers market consists of revenues earned by entities by providing services such as clinical trial services, sample collection and biobanking services, custom biomarker assay development, data analysis and interpretation services, companion diagnostics services, point-of-care testing services, and regulatory and compliance support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood-based biomarkers market includes sales of diagnostic kits, reagents, assay platforms, analyzers, and related consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The blood-based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth during the forecast period is expected to be driven by the expansion of AI and machine learning in biomarker analysis, a higher demand for early disease detection, the growth of telemedicine and remote diagnostics, the increasing prevalence of chronic diseases, and greater health awareness among consumers. Key trends during this period will include AI-driven biomarker discovery, advancements in liquid biopsy, integration of multi-omics, development of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the blood-based biomarkers market. Cardiovascular diseases, which encompass disorders affecting the heart and blood vessels such as coronary artery disease, heart failure, and stroke, are becoming more common due to risk factors such as poor diet and rising obesity rates. Blood-based biomarkers play a crucial role in diagnosing and monitoring these diseases by offering valuable information on disease progression, risk assessment, and treatment response through measurable substances in the blood. A global health research initiative by the National Center for Biotechnology Information in September 2024 projected a 90% increase in cardiovascular disease cases from 2025 to 2050, with cardiovascular deaths expected to reach 35.6 million by 2050. This rising incidence of cardiovascular diseases is contributing to the market growth for blood-based biomarkers.
Leading companies in the blood-based biomarkers market are focusing on technological innovations, such as high-accuracy blood biomarker tests, to assist in diagnosing diseases such as Alzheimer’s disease. These tests use specific biomarkers in the blood to detect or monitor health conditions with high precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, introduced the LucentAD p-Tau 217 test, a high-accuracy blood biomarker test designed to help physicians diagnose Alzheimer’s disease in adults with cognitive impairment. The test measures phosphorylated tau protein at threonine 217 (p-Tau 217), which is strongly linked to Alzheimer’s pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test provides over 90% accuracy, fulfilling stringent diagnostic criteria, and is meant to be used alongside other diagnostic tools rather than independently.
In December 2023, Danaher, a US-based provider of diagnostic, life sciences, and environmental solutions, acquired Abcam for $5.7 billion. This acquisition allows Danaher to enhance its life sciences portfolio by incorporating Abcam’s leading protein consumables and research tools. Abcam, a UK-based life sciences company, specializes in the development and distribution of research tools, including antibodies, assays, and reagents.
Major players in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG.
North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blood-based biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the blood-based biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Blood-based biomarkers are substances in the blood that can be measured to indicate the presence, progression, or response to a disease. They are primarily used for early detection, helping to personalize treatment plans and monitor treatment effectiveness with minimal invasiveness.
These biomarkers can be categorized into several types, including genetic, protein, metabolic, cell-based, and epigenetic biomarkers. Genetic biomarkers, which are based on DNA or RNA, identify genetic variations, mutations, or expression patterns linked to specific diseases or treatment responses. They are utilized in various advanced technologies, such as next-generation sequencing, polymerase chain reaction, immunoassays, and mass spectrometry. These biomarkers play a critical role in diagnosing and monitoring diseases such as cancer, cardiovascular conditions, neurological disorders, and immunological diseases. Key users of these biomarkers include hospitals, clinics, diagnostic labs, research institutes, and other healthcare providers.
The blood-based biomarkers market research report is one of a series of new reports that provides blood-based biomarkers market statistics, including the blood-based biomarkers industry global market size, regional shares, competitors with the blood-based biomarkers market share, detailed blood-based biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the blood-based biomarkers industry. This blood-based biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The blood-based biomarkers market consists of revenues earned by entities by providing services such as clinical trial services, sample collection and biobanking services, custom biomarker assay development, data analysis and interpretation services, companion diagnostics services, point-of-care testing services, and regulatory and compliance support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood-based biomarkers market includes sales of diagnostic kits, reagents, assay platforms, analyzers, and related consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Blood Based Biomarkers Market Characteristics3. Blood Based Biomarkers Market Trends And Strategies4. Blood Based Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Blood Based Biomarkers Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Blood Based Biomarkers Market34. Recent Developments In The Blood Based Biomarkers Market
5. Global Blood Based Biomarkers Growth Analysis And Strategic Analysis Framework
6. Blood Based Biomarkers Market Segmentation
7. Blood Based Biomarkers Market Regional And Country Analysis
8. Asia-Pacific Blood Based Biomarkers Market
9. China Blood Based Biomarkers Market
10. India Blood Based Biomarkers Market
11. Japan Blood Based Biomarkers Market
12. Australia Blood Based Biomarkers Market
13. Indonesia Blood Based Biomarkers Market
14. South Korea Blood Based Biomarkers Market
15. Western Europe Blood Based Biomarkers Market
16. UK Blood Based Biomarkers Market
17. Germany Blood Based Biomarkers Market
18. France Blood Based Biomarkers Market
19. Italy Blood Based Biomarkers Market
20. Spain Blood Based Biomarkers Market
21. Eastern Europe Blood Based Biomarkers Market
22. Russia Blood Based Biomarkers Market
23. North America Blood Based Biomarkers Market
24. USA Blood Based Biomarkers Market
25. Canada Blood Based Biomarkers Market
26. South America Blood Based Biomarkers Market
27. Brazil Blood Based Biomarkers Market
28. Middle East Blood Based Biomarkers Market
29. Africa Blood Based Biomarkers Market
30. Blood Based Biomarkers Market Competitive Landscape And Company Profiles
31. Blood Based Biomarkers Market Other Major And Innovative Companies
35. Blood Based Biomarkers Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Blood Based Biomarkers Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on blood based biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for blood based biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blood based biomarkers market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Genetic Biomarkers; Protein Biomarkers; Metabolic Biomarkers; Cell-Based Biomarkers; Epigenetic Biomarkers2) By Technology: Next-Generation Sequencing; Polymerase Chain Reaction; Immunoassays; Mass Spectrometry; Other Technologies
3) By Application: Cancer; Cardiovascular Diseases; Neurological Diseases; Immunological Diseases; Other Applications
4) By End Users: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutes; Other End Users
Subsegments:
1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations; Ribonucleic Acid (RNA) Expression Profiles; Single Nucleotide Polymorphisms (SNPs); Copy Number Variations (CNVs); Gene Fusions2) By Protein Biomarkers: Enzymes; Hormones; Cytokines; Tumor Markers; Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles; Amino Acid Levels; Glucose And Lactate Levels; Organic Acids; Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs); Immune Cell Profiling; Stem Cells; Platelets; Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns; Histone Modifications; Non-Coding Ribonucleic Acid (RNA); Chromatin Accessibility; Epigenetic Enzyme Activity
Key Companies Profiled: Siemens Healthineers AG; Agilent Technologies Inc; Eisai Co Ltd; Sysmex Corporation; Exact Sciences Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Siemens Healthineers AG
- Agilent Technologies Inc
- Eisai Co Ltd
- Sysmex Corporation
- Exact Sciences Corporation
- Guardant Health
- Quanterix Corporation
- Illumina Inc
- QIAGEN NV
- GENFIT
- Foundation Medicine Inc
- Adaptive Biotechnologies Corporation
- GRAIL LLC
- Biodesix Inc
- Cleveland Diagnostics Inc
- Creative Diagnostics
- Epigenomics AG
- C2N Diagnostics
- Diadem srl
- Proteomedix AG